The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Fludeoxyglucose F 18 · FLUDEOXYGLUCOSE F-18 300 mCi/mL · Injection · Intravenous · The University of Utah DBA Cyclotron Radiochemistry Lab / Huntsman Cancer Institute
NDC 67939-0010-50 · 50 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| SOFIE Co. dba SOFIE | FLUDEOXYGLUCOSE F-18 20 mCi/mL | Jul 15, 2026 | Sep 2, 2026 |
| The University of Utah DBA Cyclotron Radiochemistry Lab / Huntsman Cancer Institute | FLUDEOXYGLUCOSE F-18 300 mCi/mL | Jul 15, 2026 | Sep 2, 2026 |
| Washington University School of Medicine | FLUDEOXYGLUCOSE F-18 300 mCi/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Fludeoxyglucose F 18 — NDC 67939-0010-50," retrieved September 3, 2026, https://drugdashboards.com/drug/67939001050.
Free to cite with attribution — see how the data is put together.